RxDoctor Payments Data

Emily Ruden, MD

Cardiovascular Disease · Noblesville, INNPI 1316180474

Payments from drug & device makers

$900in general payments, 2019–2025

Across 49 payments — averaging $18.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$156
  • Johnson & Johnson$103
  • Boston Scientific$93
  • AstraZeneca$88
  • E.r. Squibb & Sons, L.L.C.$54
  • Amarin Pharma, Inc.$52
  • plus $354 from 14 others

What the payments were for

  • Food & beverage$88698%
  • Education$142%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$900 in reported general payments places this provider in the 30th percentile of 408 cardiovascular disease providers in Indiana.

See all cardiovascular disease providers in Indiana

Medicare billing

Part B allowed, 2024
$141,955
Medicare patients
933
Services billed
2,046

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban386$510,567
JardianceEmpagliflozin108$165,027
EntrestoSacubitril/Valsartan69$95,020
Repatha SureclickEvolocumab56$67,353
XareltoRivaroxaban36$48,231
FarxigaDapagliflozin Propanediol19$17,780
OzempicSemaglutide12$17,080
VascepaIcosapent Ethyl11$10,669
Ranolazine ErRanolazine55$9,032
Metoprolol Succinate347$4,061
Rosuvastatin Calcium329$3,413
Spironolactone415$3,307
Atorvastatin Calcium421$3,150
Carvedilol317$2,106
Ezetimibe75$2,045

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$37$510,567386 claims
Boehringer IngelheimJardiance$21$165,027108 claims
NovartisEntresto$156$95,02069 claims
Johnson & JohnsonXarelto$103$48,23136 claims
AstraZenecaFarxiga$88$17,78019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 408 cardiovascular disease providers in Indiana.

Other cardiovascular disease in Noblesville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →